{"id":8282,"date":"2025-08-09T12:05:15","date_gmt":"2025-08-09T09:05:15","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8282"},"modified":"2025-08-09T12:05:15","modified_gmt":"2025-08-09T09:05:15","slug":"lipoproteins-and-lipoproteina-a-gps-practical-guide-published-august-2025","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/lipoproteins-and-lipoproteina-a-gps-practical-guide-published-august-2025\/","title":{"rendered":"Lipoproteins and Lipoprotein(a): A GP\u2019s Practical Guide Published: August 2025"},"content":{"rendered":"
Lipoproteins and Lipoprotein(a): A GP\u2019s Practical Guide<\/div>\n
<\/div>\n
Published: August 2025<\/div>\n
Source: American Heart Association (AHA) \u2013 Clinicians\u2019 Guide to Frequently Asked Questions About Lipoprotein(a) Testing<\/div>\n
With added background on apolipoproteins and cholesterol transport for clarity<\/div>\n
<\/div>\n
1. Why do fats need proteins in the blood?<\/div>\n
\u2022 Fats (lipids) do not dissolve in water, and blood is water-based.<\/span><\/div>\n
\u2022 To move through the bloodstream, fats attach to apolipoproteins, forming lipoproteins \u2014 particles that safely transport cholesterol and triglycerides to where the body needs them.<\/span><\/div>\n
<\/div>\n
2. Main types of lipoproteins (from least to most dense):<\/div>\n
\u00a0 \u00a0 \u00a0 \u00a0 1. Chylomicrons \u2013 Rich in triglycerides; deliver dietary fat from intestines.<\/span><\/div>\n
\u00a0 \u00a0 \u00a0 \u00a0 2. VLDL (Very Low-Density Lipoprotein) \u2013 Carries triglycerides made in the liver to tissues.<\/span><\/div>\n
\u00a0 \u00a0 \u00a0 \u00a03. IDL (Intermediate-Density Lipoprotein) \u2013 Transitional form from VLDL to LDL.<\/span><\/div>\n
\u00a0 \u00a0 \u00a0 \u00a04. LDL (Low-Density Lipoprotein) \u2013 Delivers cholesterol to tissues; major cause of plaque build-up (\u201cbad cholesterol\u201d).<\/span><\/div>\n
\u2022 Main protein: ApoB-100 \u2014 one per particle, making ApoB a direct count of harmful particles.<\/span><\/div>\n
\u00a0 \u00a0 \u00a0 \u00a05. HDL (High-Density Lipoprotein) \u2013 Removes cholesterol from tissues to the liver (\u201cgood cholesterol\u201d).<\/span><\/div>\n
\u2022 Main protein: ApoA-I \u2014 generally protective.<\/span><\/div>\n
\u00a0 \u00a0 \u00a0 \u00a06. Lp(a) (Lipoprotein(a)) is a genetically determined, modified form of LDL \u2014 People with elevated Lp(a) have both regular LDL and a genetically modified LDL particle that carries an extra Apo(a) protein, adding extra cardiovascular risk.\u00a0<\/span><\/div>\n
Lp(a) contains the standard ApoB-100 found in LDL, but also carries an extra protein called Apo(a). This added component makes it behave differently from regular LDL, increasing its tendency to stick to artery walls and promote atherosclerosis.<\/div>\n
So most people\u2019s main problem is high LDL, but for the 1 in 5 with genetically high Lp(a), it can add significant risk on top of LDL.<\/div>\n
<\/div>\n
3. ApoA vs Apo(a) \u2014 Avoid the name trap of these proteins<\/div>\n
\u2022 ApoA-I \u2192 Found in HDL, promotes cholesterol clearance, usually heart-protective.<\/span><\/div>\n
\u2022 Apo(a) \u2192 Found only in Lp(a), harmful, increases clot and plaque risk.<\/span><\/div>\n
\u2022 They sound similar but are completely different proteins with opposite health effects.<\/span><\/div>\n
<\/div>\n
4. What is Lp(a) and why it matters<\/div>\n
\u2022 Structure: LDL + ApoB-100 + extra Apo(a) protein.<\/span><\/div>\n
\u2022 Genetics: Levels are fixed by the LPA gene \u2014 not affected by diet or exercise.<\/span><\/div>\n
\u2022 Risks: Raises likelihood of coronary artery disease, stroke, and aortic valve stenosis.<\/span><\/div>\n
\u2022 Prevalence: Elevated in about 15\u201320% of the general population; more common in African and South Asian ancestry.\u00a0\u00a0<\/span><\/div>\n
<\/div>\n
5. When to test for Lp(a)<\/div>\n
\u2022 Not a universal screening \u2014 test at least once in life if:<\/span><\/div>\n
\u2022 Premature heart disease (men <55, women <65)<\/span><\/div>\n
\u2022 Strong family history of early ASCVD<\/span><\/div>\n
\u2022 Familial hypercholesterolemia (FH)<\/span><\/div>\n
\u2022 Recurrent events despite good LDL control<\/span><\/div>\n
\u2022 Unexplained high LDL or suspected FH<\/span><\/div>\n
\u2022 Remember: LDL and ApoB are the primary targets in prevention; Lp(a) is a secondary risk-enhancing factor but critical in those with genetic elevation.<\/span><\/div>\n
<\/div>\n
6. How to explain Lp(a) to patients<\/div>\n
<\/div>\n
\u201cThink of Lp(a) as LDL with a dangerous upgrade \u2014 it has an extra protein that makes it stick more tightly to artery walls. You can\u2019t change it with lifestyle, but knowing your level helps us protect you better.\u201d<\/div>\n
<\/div>\n
7. Managing high Lp(a)<\/div>\n
\u2022 No approved drugs yet to directly lower Lp(a).<\/span><\/div>\n
\u2022 Reduce total cardiovascular risk by:<\/span><\/div>\n
\u2022 Aggressive LDL lowering (statins, ezetimibe, PCSK9 inhibitors)<\/span><\/div>\n
\u2022 Heart-healthy lifestyle (diet, activity, weight, no smoking)<\/span><\/div>\n
\u2022 Screening first-degree relatives (cascade screening)<\/span><\/div>\n
\u2022 Risk threshold: >50 mg\/dL or >125 nmol\/L.<\/span><\/div>\n
<\/div>\n
8. Cascade screening<\/div>\n
\u2022 Test parents, siblings, and children of affected patients.<\/span><\/div>\n
\u2022 Benefits: early detection, timely prevention, family awareness.<\/span><\/div>\n
<\/div>\n
9. Coverage and codes<\/div>\n
\u2022 Many insurers cover one-time testing with appropriate documentation.<\/span><\/div>\n
\u2022 Examples:<\/span><\/div>\n
\u2022 ICD-10: Z83.430 (family history of elevated Lp(a)), E78.01 (familial hypercholesterolemia)<\/span><\/div>\n
\u2022 CPT: 83695 (lab billing)<\/span><\/div>\n
<\/div>\n
10. New treatments on the horizon<\/div>\n
\u2022 Lipoprotein apheresis is used in extreme cases.<\/span><\/div>\n
\u2022 Clinical trials are underway for Lp(a)-lowering drugs \u2014 results expected in coming years.<\/span><\/div>\n
<\/div>\n
Key GP take-home points<\/div>\n
1. Fats need apolipoproteins to travel \u2014 HDL (ApoA-I) is protective, LDL (ApoB) is harmful.<\/span><\/div>\n
2. Lp(a) = LDL + extra Apo(a) protein \u2014 genetically determined, sticky, high-risk.\u00a0<\/span><\/div>\n
Lp(a) is elevated in a minority of people. This is why the AHA and other guidelines classify Lp(a) as an additional (\u201csecondary\u201d) risk-enhancing factor \u2014 it\u2019s not the first target for management, but knowing if it\u2019s elevated is crucial in high-risk or unexplained cases.<\/div>\n
3. Primary aim: Control LDL\/ApoB in everyone.<\/span><\/div>\n
4. Secondary aim: Check Lp(a) once in high-risk patients \u2014 about 1 in 5 will have it elevated.<\/span><\/div>\n
5. Use cascade screening to protect families.<\/span><\/div>\n
6. Focus on total risk reduction while awaiting Lp(a)-specific therapies.<\/span><\/div>\n
<\/div>\n
\ud83d\udd17 Educational Resource: www.heart.org\/lpadiscovery<\/div>\n
<\/div>\n
https:\/\/www.lipid.org\/lpaguide<\/div>\n","protected":false},"excerpt":{"rendered":"

Lipoproteins and Lipoprotein(a): A GP\u2019s Practical Guide Published: August 2025 Source: American Heart Association (AHA) \u2013 Clinicians\u2019 Guide to Frequently Asked Questions About Lipoprotein(a) Testing With added background on apolipoproteins and cholesterol transport for clarity 1. Why do fats need proteins in the blood? \u2022 Fats (lipids) do not dissolve in water, and blood is […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8282","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8282"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8282\/revisions"}],"predecessor-version":[{"id":8283,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8282\/revisions\/8283"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}